Indeed, low-dose anti-VEGFR2 did not impact tumour volume (Supplementary Figure S3D) and did not change the frequency of Treg and Gr-MDSCs (Supplementary Figure S2E,F). The gene discussed is KDR; the disease is neoplasm.